Auckland 1999


28 January 1999 – 29 January 1999

Will be held in the Dept of Pharmacology & Clinical Pharmacology University of Auckland, Park Road, Auckland, New Zealand on Friday 29th January 1999

Thursday 28th January 1999

19:00 PAWS/PAGANZ Social Event

Friday 29th January 1999:

08:30 Registration

09:00 Welcome. Nick Holford

09:15 Combining PK and PD data during population PK/PD analysis. Janet Wade

10:15 Coffee/Tea

10:30 Poster Session

12:00 Lunch


Friday 29th January 1999

13:00 Covariate model building – automated methods and influential individuals diagnostics. Mats Karlsson

14:00 Model Building Practices: Disease Progress Models. Nick Holford

15:00 Coffee/Tea

15:15 Population PK/PD – The Good, the Bad, and the Ugly. Diane Mould

16:15 Peri-Operative Pain Control in Paediatrics with Paracetamol. Brian Anderson

17:00 Meeting Close

FEES: Registration for the meeting is NZ$100. Fees include coffee/tea and lunch and conference materials.

ACCOMMODATION: Accommodation close to the School of Medicine includes:

Grafton Oaks Hotel

$112.50 (incl. GST) – Corporate Charge back rate

$145.00 (incl. GST) – Normal

Ph: 309 0167

Fax: 377 5962

Sheraton Auckland Hotel

$190.00 +GST (Superior)

$205 +GST (Executive)

(both suit up to 2 people)

Ph: 379 5132

Fax: 377 9367


Biographical Sketches of Participating Faculty

Janet R. Wade, Ph.D.

Dr. Wade is a graduate of Aberdeen University, Scotland (B.Sc Hons – Pharmacology) and Glasgow University, Scotland (Ph.D., Thesis title – Pharmacokinetics/Pharmacodynamics of the ACE Inhibitors). Between 1981 and 1986 she worked for Syntex, Edinburgh, in the Drug Metabolism and Pharmacokinetics department. In late 1986 she returned to university and finished her Ph.D. in 1990. Post doctoral studies were carried out at Glasgow University, Scotland (Prof. Brian Whiting), Uppsala University, Sweden (Dr. Mats Karlsson) and finally UCSF, USA (Dr. Nancy Sambol). She joined the Swedish Medical Products Agency in 1995 as a pharmacokinetic assessor and has been there for just over three years. Her main field of interest are pharmacokinetic/ pharmacodynamic data analysis, with particular emphasis on the application of the population approach. She is also interested in drug drug interactions and the use of in vitro systems for predicting these and was involved in the writing of the European guideline on this subject. She is a member of the AAPS and the DIA.


Mats O. Karlsson, Ph.D.

Dr. Karlsson obtained both his pharmacy degree (M.Sc., 1984) and his doctorate (1989) from Uppsala University, Sweden. His career in academia continued with post doctoral studies in Uppsala, Glasgow and finally San Francisco under the guidance of Prof Lewis Sheiner. Dr. Karlsson became an Assoc. Prof. at Uppsala University upon his return in 1994, and where he has remained. Lately, he has been involved in the development of population PK/PD models in various drug development areas (cancer, cardiovascular, Parkinson, urogenital) as well as methododological research into nonlinear mixed effects model building (e.g. by the creation of Xpose).


Nicholas HG Holford

Dr Holford obtained his medical qualifications (MB. ChB., MRCP) in the United Kingdom He worked at UC San Francisco from 1975-1983 initially as a Fellow in Clinical Pharmacology and subsequently as a Faculty member. During this period he developed an interest in the quantitative aspects of clinical pharmacology and developed software for pharmacokinetic-dynamic analysis. His computer program MKMODEL has been published and used worldwide since 1985. In 1983 he moved to Auckland, New Zealand to take up an appointment in the Department of Pharmacology and Clinical Pharmacology, University of Auckland. Until 1989 he had a part time appointment as a Specialist in Internal Medicine at Auckland Hospital. During this period he was elected a Fellow of the Royal Australasian College of Physicians. In 1990 he had a 9 month sabbatical leave at Hoffmann-La Roche, Basel, Switzerland where he was involved in developing a population approach to clinical pharmacology in the drug development process. More recently he has been involved in the development of a multimedia teaching program on the clinical pharmacological aspects of drug development (RIDO). A major commitment has been made to the development of a clinical trials simulation and analysis system and Dr Holford is a member of the Scientific Advisory Board for Pharsight Inc. Dr Holford was on sabbatical in 1998 and worked on a variety of projects related to disease progress modelling and clinical trial simulation. He is currently involved in describing the effects of anti-Parkinsonian agents on the progression of Parkinsons’s disease. In 1995 he was invited to be a founding member of the Center for Drug Development Science Scientific Advisory Board. The CDDS is based at Georgetown University, Washington DC and is concerned with promoting research and teaching on the scientific basis of drug development. Dr Holford is currently an Assoociate Professor at the University of Auckland. He is co-editor of The In Vivo Study of Drug Actionand the recently published 4th edition of Avery’s Drug Treatment. He has been consulting editor for Clinical Pharmacokinetics since 1995.


Diane R Mould

Dr. Mould graduated from Stevens Institute of Technology in 1984 with a BS in Chemical Engineering and Chemical Biology.  She then attended the Ohio State University, where was awarded an AFPE Fellowship and an Academic Challenge Fellowship, and obtained a PhD in Pharmaceutics and  Pharmaceutical Chemistry in 1989.  After graduation, she worked with Dr. Tom Ludden at The University of Texas at San Antonio to learn the population approach to pharmacokinetic modeling.  She is a member of several scientific societies including Rho Chi, Sigma Xi, Phi Kappa Phi, AAPS and ASCPT.  She has published 10 articles and 2 book chapters on pharmacokinetics and pharmacokinetic/dynamic modeling.  Her research interests include XAFS analysis, QSAR + AI for molecular modeling, and population PK and PK/PD analysis.  She is currently working for SmithKline-Beecham Pharmaceuticals as an assistant director in the department of Drug Metabolism and Pharmacokinetics.


Brian Anderson

Dr Anderson gained his medical qualification at Otago, NZ in 1980 (MBChB) and went on to specialise in both anaesthesia (FANZCA, 1987) and intensive care (FFICANZA, 1990). He is currently employed as a pediatric intensivist/anaesthetist at the Starship Children’s Hospital, Auckland and is also responsible for the Acute Pain Service. He is currently enrolled in a PhD program in the Dept of Pharmacology, University of Auckland where is studying pharmacokinetic and pharmacodynamic approaches to improving pain control in children.